US Pharma MarketingActio Biosciences, which will receive $820 million up front in the deal, adds to a major upswing in private biotech buyouts seen throughout this year.
Jazz to buy rare epilepsy drugmaker in potentially $1.3B deal
Actio Biosciences, which will receive $820 million up front in the deal, adds to a major upswing in private biotech buyouts seen throughout this year.
Source: BioPharma Dive